Stock Fundamentals

Company Information

Company Name
Tarsus Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US87650L1035
CIK: 0001819790
CUSIP: 87650L103
Currency: USD
Full Time Employees: 370
Phone: 949 418 1801
Fiscal Year End: December
IPO Date: Oct 16, 2020
Description:

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Address:

17700 Laguna Canyon Road, Irvine, CA, United States, 92618

Directors & Officers

Name Title Year Born
Dr. Bobak R. Azamian M.D. Co-Founder, President, CEO & Chairman NA
Mr. Jeffrey S. Farrow CPA CFO & Chief Strategy Officer 1962
Dr. Seshadri Neervannan Ph.D. Chief Operating Officer 1968
Dr. Bryan Wahl J.D., M.D. General Counsel & Corporate Secretary 1978
Mr. Aziz Mottiwala M.B.A. Chief Commercial Officer 1978
Mr. David Nakasone Head of Investor Relations NA
Ms. Adrienne Kemp Senior Director of Corporate Communications NA
Mr. Matthew Rossen M.B.A. Vice President of Marketing 1978
Mr. Scott Youmans Vice President of Sales NA
Ms. Dianne C. Whitfield M.S.W. Chief Human Resources Officer 1977

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Mar 19, 2026 Bryan Wahl N/A Sale 4.23K $67.00 $283.48K
Mar 19, 2026 Dianne C Whitfield N/A Sale 4.17K $67.00 $279.66K
Mar 19, 2026 Elizabeth Yeu Lin N/A Sale 390.00 $67.00 $26.13K
Mar 19, 2026 Jeffrey S Farrow N/A Sale 2.19K $67.00 $146.46K
Mar 19, 2026 Bobak R Azamian N/A Sale 11.96K $67.00 $801.59K
Mar 18, 2026 Bobak R Azamian N/A Sale 11.67K $68.71 $801.64K
Mar 18, 2026 Bryan Wahl N/A Sale 4.13K $68.71 $283.43K
Mar 18, 2026 Dianne C Whitfield N/A Sale 4.07K $68.71 $279.72K
Mar 18, 2026 Elizabeth Yeu Lin N/A Sale 379.00 $68.71 $26.04K
Mar 18, 2026 Jeffrey S Farrow N/A Sale 2.13K $68.71 $146.56K
Mar 17, 2026 Bobak R Azamian N/A Sale 10.97K $69.42 $761.68K
Mar 17, 2026 Jeffrey S Farrow N/A Sale 2.11K $69.42 $146.55K
Mar 17, 2026 Elizabeth Yeu Lin N/A Sale 375.00 $69.42 $26.03K
Mar 17, 2026 Dianne C Whitfield N/A Sale 4.03K $69.42 $279.69K
Mar 17, 2026 Bryan Wahl N/A Sale 4.08K $69.42 $283.51K
Mar 16, 2026 William J Phd Link N/A Sale 12.50K $68.79 $859.88K
Dec 24, 2025 Bobak R Azamian N/A Sale 6.00K $82.51 $495.06K
Dec 16, 2025 Dianne C Whitfield N/A Sale 7.40K $80.10 $592.50K
Sep 24, 2025 Bobak R Azamian N/A Sale 6.00K $55.37 $332.22K
Sep 08, 2025 William J Phd Link N/A Sale 27.12K $57.00 $1.55M

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Deep Track Capital, LP 3.60M Mar 31, 2026 8.37% $4.12 19.84%
BlackRock Inc 3.55M Mar 31, 2026 8.26% $0.00 -6.28%
RTW INVESTMENTS, LLC 3.35M Mar 31, 2026 7.78% $2.34 0.32%
Paradigm Biocapital Advisors LP 2.56M Mar 31, 2026 5.96% $3.67 0.00%
Vanguard Group Inc 2.40M Dec 31, 2025 5.58% $0.00 5.61%
HHG PLC 2.24M Mar 31, 2026 5.21% $0.08 16.09%
Morgan Stanley - Brokerage Accounts 1.94M Mar 31, 2026 4.52% $0.01 -4.73%
Jennison Associates LLC 1.71M Mar 31, 2026 3.98% $0.08 -23.23%
Assenagon Asset Management SA 1.28M Mar 31, 2026 2.98% $0.14 13.52%
Bank of America Corp 1.19M Mar 31, 2026 2.78% $0.01 57.55%
TANG CAPITAL MANAGEMENT LLC 1.19M Mar 31, 2026 2.76% $4.23 0.00%
Geode Capital Management, LLC 1.12M Mar 31, 2026 2.61% $0.00 18.29%
State Street Corp 978.21K Mar 31, 2026 2.27% $0.00 5.29%
Driehaus Capital Management LLC 926.13K Mar 31, 2026 2.15% $0.48 -21.01%
Lord, Abbett & Co LLC 842.31K Mar 31, 2026 1.96% $0.19 -1.56%
D. E. Shaw & Co LP 791.15K Mar 31, 2026 1.84% $0.03 28.61%
Amvescap Plc. 742.50K Mar 31, 2026 1.73% $0.01 -26.66%
FMR Inc 733.33K Mar 31, 2026 1.70% $0.00 13.32%
Frazier Life Sciences Management, L.P. 728.64K Mar 31, 2026 1.69% $1.32 0.00%
Millennium Management LLC 564.58K Mar 31, 2026 1.31% $0.02 382.53%

Shares Statistics

Shares Outstanding: 43.02M
Shares Float: 32.12M
% Insiders: 307.10%
% Institutions: 10,974.60%
Short % Float: 11.78%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 1.29M 2.99% ▲ 0.36% Apr 30, 2026
2 iShares Russell 2000 ETF 929.16K 2.16% ▲ 0.85% Apr 30, 2026
3 Vanguard Institutional Extnd Mkt Idx Tr 440.58K 1.02% ▲ 1.17% Apr 30, 2026
4 PGIM Jennison Small Company A 440.54K 1.02% ▲ 1.33% Apr 30, 2026
5 Jennison SMid Cap Core Equity 434.75K 1.01% ▼ 15.22% Mar 31, 2026
6 Lord Abbett Developing Growth A 420.04K 0.98% ▲ 0.00% Mar 31, 2026
7 MEDICAL BioHealth EUR Acc 413.92K 0.96% ▲ 3.80% Apr 30, 2026
8 Fidelity Small Cap Index 383.31K 0.89% ▲ 1.11% Feb 28, 2026
9 iShares Russell 2000 Growth ETF 323.58K 0.75% ▲ 0.26% Apr 30, 2026
10 Fidelity Growth Compy Commingled Pl S 311.19K 0.72% ▲ 0.13% Mar 31, 2026

Valuation Metrics

Enterprise Value: $2.22B
Trailing P/E: 0.00
Forward P/E: 106.38

Financial Highlights

Market Cap: $2.47B
EBITDA: $-49.02M
Book Value: $8.07
Earnings/Share: $-1.11
Profit Margin: -9.02%
Operating Margin: -3.78%
ROA (TTM): -5.87%
ROE (TTM): -13.96%
Revenue (TTM): $535.08M
Revenue/Share (TTM): $12.54
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 106.90%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 3.85x 0.21x 0.39x -7.94x -1.35x
2024-12-31 4.42x 0.32x 0.40x -16.19x -0.68x
2023-12-31 6.93x 0.15x 0.26x -44.39x -0.23x
2022-12-31 14.61x 0.10x 0.15x -30.38x -0.34x
2021-12-31 15.33x 0.01x 0.07x -4.22x -0.10x
2020-12-31 31.68x 0.00x 0.03x -143.53x -0.01x
2019-12-31 70.85x -0.01x 1.10x -107.45x -0.01x
2018-12-31 13.31x 0.00x 1.57x N/A 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about TARS.US!